Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration
P William Conrad, David N Zacks, Mark W JohnsonDepartment of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USAPurpose: To determine whether the effect of a single initial intravitreal injection of bevacizumab for neovascular age-related macular d...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2008
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/434fb928208d4a47b539b54e384dd563 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|